{"organizations": [], "uuid": "21d189e9895fb83edb9990443e0346b7b5adb3f4", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-amag-gets-fda-approval-of-makena-s/brief-amag-gets-fda-approval-of-makena-subcutaneous-auto-injector-idUSASB0C5UK", "country": "US", "domain_rank": 408, "title": "BRIEF-AMAG Gets FDA Approval Of Makena Subcutaneous Auto-Injector", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-15T01:24:00.000+02:00", "replies_count": 0, "uuid": "21d189e9895fb83edb9990443e0346b7b5adb3f4"}, "author": "", "url": "https://www.reuters.com/article/brief-amag-gets-fda-approval-of-makena-s/brief-amag-gets-fda-approval-of-makena-subcutaneous-auto-injector-idUSASB0C5UK", "ord_in_thread": 0, "title": "BRIEF-AMAG Gets FDA Approval Of Makena Subcutaneous Auto-Injector", "locations": [], "entities": {"persons": [{"name": "maken", "sentiment": "none"}], "locations": [{"name": "makena", "sentiment": "none"}, {"name": "makena", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "fda approval of makena subcutaneous", "sentiment": "negative"}, {"name": "amag pharmaceuticals inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "amag", "sentiment": "none"}, {"name": "amag pharmaceuticals inc", "sentiment": "none"}, {"name": "amag pharmaceuticals", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 14 (Reuters) - Amag Pharmaceuticals Inc:\n* AMAG PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF MAKENA® (HYDROXYPROGESTERONE CAPROATE INJECTION) SUBCUTANEOUS AUTO-INJECTOR TO REDUCE THE RISK OF PRETERM BIRTH IN CERTAIN AT-RISK WOMEN\n* AMAG PHARMACEUTICALS - EXPECTS TO FILE A NEW DRUG APPLICATION THIS QUARTER FOR A NEW CHEMICAL ENTITY (BREMELANOTIDE) ​\n* AMAG PHARMACEUTICALS INC - ‍EXPECTS SUBCUTANEOUS AUTO-INJECTOR TO BE AVAILABLE IN SECOND HALF OF MARCH​\n* AMAG PHARMACEUTICALS INC - WILL CONTINUE TO OFFER IM FORMULATION OF MAKENA IN BOTH SINGLE-DOSE AND MULTI-DOSE VIALS​\n* AMAG PHARMACEUTICALS INC - ‍MAKEN‘S 7-YEAR ORPHAN DRUG EXCLUSIVITY EXPIRED EARLIER THIS MONTH​\n* AMAG PHARMACEUTICALS - ANNOUNCES FDA APPROVAL OF MAKENA (HYDROXYPROGESTERONE CAPROATE INJECTION) SUBCUTANEOUS AUTO-INJECTOR ‍​ Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-02-15T01:24:00.000+02:00", "crawled": "2018-02-15T01:45:58.005+02:00", "highlightTitle": ""}